Antonio M Grimaldi

List of Publications by Year
in descending order

23 papers	1,934 citations	686830 13 h-index	552369 26 g-index
27 all docs	27 docs citations	27 times ranked	4067 citing authors

#	Article	IF	Citations
1	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine, 2021, 19, 17.	1.8	6
2	Ipilimumab and Stereotactic Radiosurgery with CyberKnifeÂ® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers, 2021, 13, 1857.	1.7	5
3	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology, 2018, 7, e1405206.	2.1	43
4	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs, 2017, 31, 51-61.	2.2	46
5	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 2017, 27, 243-250.	0.6	12
6	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. OncoImmunology, 2017, 6, e1261242.	2.1	59
7	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. Melanoma Management, 2015, 2, 209-215.	0.1	7
8	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. Journal of Translational Medicine, 2015, 13, .	1.8	2
9	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. Journal of Translational Medicine, 2015, 13, O8.	1.8	2
10	Vemurafenib beyond progression in a patient with metastatic melanoma. Anti-Cancer Drugs, 2015, 26, 464-468.	0.7	2
11	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology, 2015, 4, e1008842.	2.1	72
12	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology, 2014, 3, e28780.	2.1	318
13	Novel Approaches in Melanoma Prevention and Therapy. Cancer Treatment and Research, 2014, 159, 443-455.	0.2	36
14	The role of MEK inhibitors in the treatment of metastatic melanoma. Current Opinion in Oncology, 2014, 26, 196-203.	1.1	39
15	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 675-683.	2.0	230
16	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	1.3	149
17	Marker Utility for Combination Therapy. Methods in Molecular Biology, 2014, 1102, 97-115.	0.4	0
18	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clinical Cancer Research, 2013, 19, 997-1008.	3.2	161

#	Article	IF	Citations
19	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. Journal of Translational Medicine, 2012, 10, 107.	1.8	112
20	Lean oncology: a new model for oncologists. Journal of Translational Medicine, 2012, 10, 74.	1.8	11
21	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	1.8	563
22	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. Journal of Clinical Oncology, 2012, 30, 8573-8573.	0.8	13
23	Clinical results of EGFR-targeted therapies in advanced colorectal cancer. European Journal of Cancer, Supplement, 2008, 6, 64-69.	2.2	1